Sernova Grants Stock Options
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/26/15 -- SERNOVA CORP. (the "Company") (TSX VENTURE: SVA) announces that, in accordance with the Company's 2015 Incentive Plan, it has granted a total of 625,000 deferred share units to its directors and a total of 2,460,000 incentive stock options to certain officers, employees and consultants of the Company, each such option being exercisable into a common share at a price of $0.26 per share on or before June 25, 2025.
About Sernova
Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch™, an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells). The therapeutic cells are protected from immune attack by Sernova's proprietary local immune protection technology.
Forward-Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Philip Toleikis, Ph.D.
President and CEO
Tel: (604) 961-2939
Ray Matthews & Associates
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
Tel: (604) 818-7778
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.06.2015 - 21:00 Uhr
Sprache: Deutsch
News-ID 403369
Anzahl Zeichen: 0
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sernova Grants Stock Options"
steht unter der journalistisch-redaktionellen Verantwortung von
Sernova Corp (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
